215 isolates showed that trimethoprim-sulfamethoxazole was the most active agent (susceptibility rate: 87.4%), followed by cefoperazone-sulbactam (48.0%).
Introduction
Chryseobacterium indologenes, formerly known as Flavobacterium indologenes, or Flavobacterium aureum, belongs to CDC group IIb. It is non-motile, catalase-positive, oxidase-positive, indole-positive, non-glucose-fermenting Gram-negative bacilli. C indologenes is a rare pathogen in humans and is not normally present in the human microflora although it is widely distributed in nature. 1 C indologenes can cause various types infections, such as bacteremia, pneumonia, meningitis, and artificial shunt infection, 2e7 especially in those who are hospitalized with long-term indwelling devices and prolonged exposure to broad-spectrum antibiotics. With increasing clinical usage of colistin and tigecycline against emerging carbapenem-resistant pathogens, such as Acinetobacter baumannii, extended-spectrum blactamases-producing Escherichia coli and Klebsiella pneumoniae, Chryseobacterium species have caused significant problems in critical healthcare setting. 8, 9 At present, even with the increasing incidence of healthcare-associated infections due to Chryseobacterium species other than C meningosepticum, 1 there is no "gold standard" or guideline for management of C indologenes infection. Vancomycin and aminoglycoside are not effective against C indologenes.
1,10
C indologenes is also intrinsically resistant to carbapenems and cephalosporins due to its production of molecular class A b-lactamase 11 and class B carbapenem-hydrolyzing b-lactamase (IND1eIND7). 12e15 Susceptibility data to tigecycline, a glycylcycline antibiotic, structurally similar to the minocycline, remain limited.
In this retrospective study, we investigated the trend in C indologenes infection after clinical usage of colistin and tigecycline. We also analyzed the clinical manifestations and microbiological characteristics of C indologenes infections.
Materials and methods

Clinical data collection
We isolated and identified C indologenes isolates from clinical samples, such as bloodstream, central venous catheter (CVC) tip, sputum, wound culture, urine culture, and other aseptic body fluid, between January 1, 2004 and September 30, 2011, at a 732-bed medical center in northern Taiwan. The sputum isolates obtained from a patient with new-onset pneumonia within 14 days and bacteremic isolates from a patient with new-onset bacteremia within 7 days were thought as the same strains and thus excluded.
We retrospectively reviewed the medical records of patients from whose samples C indologenes had been isolated. Data on underlying diseases, initial admission diagnosis, the use of indwelling catheters, ventilator, hemodialysis, administration of chemotherapy, infectious complication, and clinical outcome were recorded.
Microbiology
We examined all positive cultures following Gram staining and subcultured them on blood agar plates and eosine methylene blue agar plates for further identification. The Becton Dickinson Phoenixä Automated Microbiology System was used to identify the bacterial species according to the manufacturer's instructions. All isolates of C indologenes, Flavobacterium indologenes, or Flavobacterium aureum were included in the study. Only the blood isolates were stored at À70 C in a refrigerator and subcultured twice before further studies.
The minimal inhibitory concentration (MIC) values of cefotaxime, ceftazidime, cefepime, piperacillintazobactam, aztreonam, imipenem, meropenem, gentamicin, amikacin, ciprofloxacin, levofloxacin, chloramphenicol, trimethoprim-sulfamethoxazole (TMP-SMZ), and colistin were determined using the Becton Dickinson Phoenixä Automated Microbiology System following the manufacturer's instructions. Susceptibility to cefoperazonesulbactam and tigecycline was determined using the agar diffusion disk. An inhibition zone of more than 21 mm around a 75e35 mg cefoperazone-sulbactam disk or more than 19 mm by a 15 mg tigecycline disk (the criteria recommended by the U.S. Food and Drug Administration for Enterobacteriaceae) was regarded as susceptible. The MIC values of tigecycline for bacteremic isolates were determined using the E-test, and the susceptibility breakpoints of MICs followed those recommend by the Clinical and Laboratory Standards Institute for Pseudomonas aeruginosa and nonEnterobacteriaceae. 16 
Definitions
Significant bacteremia was defined as having the growth of C indologenes in one or more blood cultures as well as clinically manifesting signs of systemic inflammatory response syndrome. The manifestations of systemic inflammatory response syndrome include: (1) body temperature lower than 36 C or greater than 38 C; (2) heart rate greater than 90 beats/min; (3) tachypnea with greater than 20 breaths/min or an arterial partial pressure of carbon dioxide less than 32 mmHg; and (4) white blood cell count of less than 4000 cells/mm 3 or greater than 12,000 cells/mm 3 ; or the presence of greater than 10% immature neutrophils (band forms). Sputum samples were collected from hospitalized patients with the clinical diagnosis of pneumonia, as evidenced by the presence of fever, productive cough, purulent sputum, or new infiltrations in chest X-ray when compared to previous films, which were reviewed by a chest physiologist. Gram staining was performed on all sputum samples, which all yielded Gramnegative rods with more than 25 polymorphonuclear cells and less than 10 epithelial cells in the low power field (100Â) of light microscopy. No pathogens other than C indologenes, which showed significant growth in semiquantitative cultures, were noted. Co-pathogens of C indologenes pneumonia were defined as the pathogens in sputum samples within 7 days before or after the isolation of C indologenes.
Immunosuppressive therapy was defined as the use of cytotoxic agents or corticosteroids (>30 mg prednisolone daily or equivalent for !1 week). Polymicrobial bacteremia was defined as the presence of bacteria or yeasts in addition to C indologenes in the blood culture. Prior exposure to antibiotics was defined as enteral or parenteral use of antibiotics for at least 3 days, within 1 week before the isolation of C indologenes. Appropriate antibiotic therapy was defined as the use of at least one intravenous antibiotic within 72 hours of the infection onset to which the microorganism was susceptible to the antibiotics. Clinical prescriptions of colistin, tigecycline, and daptomycin were expressed as the total daily doses in 3 months per 1000 patient-days (DDD/1000PD). Mortality due to C indologenes bacteremia was defined as death within 14 days of onset of bacteremia with no other identified cause of death.
Statistical analysis
We analyzed the correlation between the consumption colistin, tigecycline, or daptomycin, and the number of patients with C indologenes bacteremia and pneumonia by multiple linear regression method. We analyzed the differences between bacteremic and pneumonic patients, with or without appropriate antibiotics using the Pearson chi-square or Fisher's exact test for dichotomous variables, and t-test for continuous variables. A significant p value was defined as less than 0.05.
Results
After the exclusion of 70 sputum isolates and 10 bacteremic isolates, there were 215 C indologenes isolatesdincluding 138 from sputum of 91 patients, 39 from bloodstream of 22 patients, and 38 from other samples of 38 patientsdavailable for the study. The correlation between colistin, tigecycline, or daptomycin consumption and the prevalence of C indologenes infections is shown in Fig. 1 . The incidence of C indologenes increased gradually after 2006 (P < 0.0001). The isolate numbers of C indologenes were correlated to increasing consumption of colistin (p Z 0.018) or tigecycline (p Z 0.049), but not daptomycin (p Z 0.051). The pulse field-gel electrophoresis profiles of bacteremic C indologenes isolates, demonstrated in Fig. 2 , showed no cluster among C indologenes bacteremic isolates.
As shown in Table 1 , there was no apparent statistical difference among patients with bacteremia and pneumonia, in terms of age, length of hospital stay, prior exposure antibiotics, and disease severity [evaluated by Acute Physiology and Chronic Health Evaluation (APACHE) II score]. The only significant factor was male gender which was more common in those with pneumonia than bacteremia (64.8% vs. 40.9%, p Z 0.040). Patients with C indologenes bacteremia had more prior stroke (45.5% vs. 23.1%, p Z 0.035) and underlying malignancy (50.0% vs. 23.1%, p Z 0.012) than those with C indologenes pneumonia. Other factors, such as ventilator-dependent status, prior corticosteroid exposure, chronic kidney disease, diabetes mellitus, and liver cirrhosis, were not different among the two groups.
Only two (9.1%) patients with C indologenes bacteremia and 19 (20.9%) patients with C indologenes pneumonia were younger than 65 years. In patients with C indologenes bacteremia, there was no documented infective Figure 1 . The correlation between colistin, tigecycline, and daptomycin consumption and prevalence of Chryseobacterium indologenes infections. Consumption of colistin, tigecycline, and daptomycin is shown, defined as daily dose (DDDs)/1000 patientdays (DDDs/1000 PDs, right y-axis). Prevalence rate is calculated as patients' number/100,000 patient-days (left, y-axis). endocarditis or neutropenia. Three (13.6%) patients with C indologenes bacteremia were thought to have community-acquired infection because the onset of bacteremia occurred less than 48 hours after admission and these patients had no recent hospitalization or visits to the emergency department in the past year. Eighteen (81.8%) of 22 patients with C indologenes bacteremia had indwelling CVC and six had CVC-related bloodstream infections, and one had concurrent bacteremia due to methicillin-resistant Staphylococcus epidermidis, which was also isolated from the CVC tip. In C indologenes bacteremic patients, one had concurrent candidemia, one had Pseudomonas bacteremia, and three had Enterococcus faecalis bacteremia. In patients with C indologenes pneumonia, there was no pleural empyema.
The common co-pathogens (Fig. 3) Tables 2 and 3 . TMP-SMZ was the most active agent, followed by cefperazonesulbactam. A total of six strains of C indologenes isolated from wound and cerebrospinal fluid were all susceptible (100%) to TMP-SMZ. However, only two wound isolates were susceptible to cefoperazone-sulbactam, and only one wound isolate was susceptible to ciprofloxacin and levofloxacin.
The mortality rates of patients with bacteremia or pneumonia, with or without appropriate antibiotics treatment, are shown in Table 4 . All pneumonic patients received appropriate antibiotics therapy according to the susceptibility for coexisting pathogens, such as A baumannii, P aeruginosa, E coli, K pneumoniae and methicillinresistant S aureus. Those patients with C indologenes bacteremia had a higher in-hospital mortality rate than those with C indologenes pneumonia (63.6% vs. 35.2%, p Z 0.015) or urinary tract infection (63.6% vs. 25.0%, P Z 0.012). Even the APACHE II scores were similar in these three groups. Of 22 patients with C indologenes bacteremia, eight died within 14 days after onset of bacteremia.
Discussion
As stated previously, C indologenes is ubiquitous in nature and is found in soil, plants, food products, and water sources despite adequate chlorination. C indologenes is frequently recovered from wet surfaces and water sources in the hospital environment. In 1993, Bonten et al 3 first isolated a strain of C indologenes from a tracheal aspirate in a patient with ventilator-associated pneumonia. In 1996, Hsueh et al 1 found increasing incidence of healthcareassociated infection due to Chryseobacterium species other than C meningosepticum (Elizabethkingia meningoseptica). In our study, we introduced colistin and tigecycline into clinical use at this medical center in August 2006. There was only one patient with C indologenes bacteremia before August 1, 2006 . Thereafter, the prevalence of C indologenes greatly increased. After 2006, the numbers of patients with isolated C indologenes infection correlated with the increased consumption of colistin and tigecycline. To our knowledge, this study is the first to describe a correlation between C indologenes infection and the consumption of colistin and tigecycline.
Chryseobacterium species are known to exhibit resistance to aminoglycosides, tetracyclines, chloramphenicol, erythromycin, clindamycin, and teicoplanin. 1, 17, 18 Most Chryseobacterium isolates are also resistant to colistin. 19 C indologenes can produce several kinds of b-lactamase. 11e15 It is possible that C indologenes may potentially survive well in the environment, if there is frequent exposure to broad-spectrum antibiotics, such as third-or fourth-generation cephalosporins and carbapenems. Increased use of broad-spectrum antibiotics, such as colistin and tigecycline, especially aerosol colistin therapy, may cause collateral damage and increase healthcareassociated C indologenes infections. 8, 20 Nosocomial pneumonia and catheter-related bacteremia accounted for most cases of C indologenes infections. 1, 21, 22 In this study, which included 22 cases of bacteremia, 91 of pneumonia, and 38 of other infections, all but three were healthcare-associated infections. Accordingly, 18 of 22 cases of C indologenes bacteremia had CVC (data not shown). Those findings are compatible with the published data, 1, 21, 22 suggesting that indwelling devices are frequent causes of C indologenes bloodstream infection. 7 The production of biofilm on indwelling devices and protease activity may play an important role in the virulence of invasive C indologenes infections. 23 Effective empirical treatment for C indologenes infections remains uncertain due to limited data in the literature. In an earlier study conducted by Hsueh et al 1 in 1996, all C indologenes isolates from the bloodstream were uniformly susceptible to piperacillin, and 92% isolates were susceptible to cefoperazone, ceftazidime, and minocycline. Susceptibility to TMP-SMZ, ofloxacin, and ciprofloxacin was variable. 1 The isolates were consistently resistant to other b-lactam antibiotics, including aztreonam and imipenem, aminoglycosides, erythromycin, clindamycin, or teicoplanin. 1 In 2004, Kirby et al 10 found that TMP-SMZ, newer fluoroquinolones, ceftazidime, cefepime, and piperacillin-tazobactam showed reasonable activity against more than 80% of the study isolates. In 2010, Lin et al 7 suggested that only newer fluoroquinolones and TMP-SMZ could possibly represent the most appropriate antimicrobial agents. In this study, we found that piperacillintazobactam and newer fluoroquinolones are no longer reliable due to decreased susceptibility. On the other hand, TMP-SMZ and cefoperazone-sulbactam remained as reliable antimicrobial agents to C indologenes, especially for bloodstream infections. The usefulness of vancomycin against Chryseobacterium infections has recently been questioned, 1, 10, 18, 24 and vancomycin has not been included in routine susceptibility testing. However, minocycline has been shown to be active in vitro against C indologenes isolates, with a susceptible rate of 92e100%. 1, 25 There are limited data on susceptibility to tigecycline of C meningosepticum isolates. 20 This is the first study to evaluate the susceptibility of C indologenes to tigecycline, and 52% of 27 bacteremic isolates were susceptible in vitro to tigecycline, as determined by MICs (E-test). However, tigecycline has not been recommended to treat bloodstream infections. Among sputum isolates, the susceptibility rate of tigecycline was higher (39.1%) than that of fluoroquinolones, including levofloxacin (32.6%) and ciprofloxacin (29.0%); thus tigecycline could not be recommended for critically ill patients with presumed C indologenes infections. Our study revealed, in comparison with published data, an increased resistance rate of C indologenes to previously potent antibiotics, including fluoroquinolones, and we hypothesized that a resistant pattern of C indologenes may evolve over time and vary according to different trends of antibiotic usage. 7 Hsueh et al in 1996 21 suggested that removal of the indwelling device is not necessary for C indologenes bacteremia. Lin et al 7 in 2010 also found that C indologenes can be eradicated with appropriate antibiotics without removal of CVC. In this study, we found that there was a significant benefit from using appropriate antibiotics for cases of C indologenes bacteremia with or without removal of CVC (P Z 0.04), although most patients died later due to an underlying disease. However, no significant benefit of appropriate antibiotics was noted for C indologenes pneumonia. The reason may be the clinical problem in distinguishing true pathogens from respiratory tract colonization with the results of the growth of C indologenes in respiratory secretions. In addition, many patients with pneumonia may have concurrent pathogens other than C indologenes. Based on these observations, it is likely that co-infections or colonization by pathogens which secrete carbapenem-hydrolyzing b-lactamase, such as C indologenes, can cause higher treatment failure rate and higher mortality rate. 26 The present study has several limitations. First, this is a retrospective study, and missing data may hide potential risk factors which were not documented in records. Second, the pathogenicity and virulence factors of C indologenes remain unclear. Our patients with C indologenes isolated from wound, cerebrospinal fluid, or ascites, were not compared due to the limited number of cases. Third, the introduction of an aggressive method for infection control, such as care bundles for catheter-related bloodstream infection or ventilator-associated pneumonia, in the intensive care units since 2009 and the general wards since 2012, may influence the prevalence of C indologenes infections. Lastly, the results of susceptibility testing varied because of different testing methods. Disk diffusion methods are especially unreliable, and broth microdilution should be used, if possible. 24 Although the E-test has been suggested as a possible alternative for testing the susceptibility of certain antibiotics, 27 only strains from bloodstream in this study were available and examined. A well-designed prospective study to address these four limitations may be necessary in the future to observe the change of C indologenes infections after restricting the use of tigecycline and colistin.
In conclusion, the present study demonstrated the increasing prevalence of C indologenes infection since colistin and tigecycline were introduced into clinical use. C indologenes bacteremia resulted in a higher mortality rate than pneumonia did, and the therapeutic benefit from appropriate antibiotics was more evident in the former infection entity. According to in vitro susceptibility study, TMP-SMZ and cefoperazone-sulbactam may be potential antimicrobial agents for C indologenes infections.
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